Animal models of 'anxiety': Where next?

Behavioural Pharmacology

Volumn 8, Issue 6-7, 1997, Pages 477-496

  Rodgers, R J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Animal models Anxiety; Anxiolytics; Behavioural validation; Defensive repertoire; Disorders of defence; Evolutionary perspective; Panicolytics; Pharmalogical validation

Indexed keywords

ALPRAZOLAM; ANXIOLYTIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CHLORDIAZEPOXIDE; CLONAZEPAM; DIAZEPAM; FLESINOXAN; FLUOXETINE; FLUVOXAMINE; GEPIRONE; IMIPRAMINE; SEROTONIN 1A AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ANXIETY NEUROSIS; DEFENSIVE BEHAVIOR; MOUSE; NONHUMAN; REVIEW; TRANQUILIZING ACTIVITY;

EID: 0030733915     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-199711000-00003     Document Type: Review

References (180)

1. Adamec RE (1990) Does kindling model anything clinically relevant? Biological Psychiatry, 27, 249-279.
2. Adamec RE (1991) Acute and lasting effects of FG-7142 on defensive and approach-attack behavior in cats - implications for models of anxiety which use response suppression. Journal of Psychopharmacology, 5, 29-55.
3. Adamec RE and Shallow T (1993) Lasting effects on rodent anxiety of a single exposure to a cat. Physiology and Behavior, 54, 101-109.
4. A receptors before and after the stress of predator exposure prevents lasting increases in anxiety-related behavior: implications for anxiety associated with posttraumatic stress disorder. Behavioral Neuroscience, 111, 435-449.
5. Adams DB (1979) Brain mechanisms for offense, defense and submission. Brain and Behavioral Sciences, 2, 201-241.
6. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington DC.
7. Andrews N and File SE (1993) Handling history modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. European Journal of Pharmacology, 235, 109-112.
8. 1A receptors in the median raphe nucleus and dorsal hippocampus may mediate anxiolytic and anxiogenic behaviours respectively. European Journal of Pharmacology, 264, 259-264.
9. Archer J (1973) Tests for emotionality in rats and mice: a review. Animal Behaviour, 21, 205-235.
10. Ballenger JC (Ed) (1991) Neurobiology of Panic Disorder. Wiley-Liss, New York.
11. Ballenger JC (1994) Pharmacological treatment of panic disorder. In: Handbook of Depression and Anxiety (Eds JA den Boer and JMA Sitsen), pp. 275-289. Marcel Dekker, New York.
12. Bandler RJ and Keay KA (1996) Columnar organization in the midbrain periaqueductal gray and the integration of emotional expression. In: Progress in Brain Research 107 (Eds G. Holstege, R Bandler and CB Saper), pp. 285-300. Elsevier Science BV, Amsterdam.
13. Barloon TJ and Noyes R (1997) Charles Darwin and panic disorder. Journal of the American Medical Association, 277, 138-141.
14. Barnett SA (1963) The Rat: A Study in Behaviour. Methuen, London.
15. Barrett JE (1991) Animal behaviour models in the analysis and understanding of anxiolytic drugs acting at serotonin receptors. In: Animal Models in Psychopharmacology (Eds B Olivier, J Mos and JL Slangen), pp. 37-52. Birkhauser Verlag, Basel.
16. 3 Antagonists and Benzodiazepines: Their Comparative Behavioural Pharmacology (Eds RJ Rodgers and SJ Cooper), pp. 59-105. J Wiley and Sons, Chichester.
17. Barrett JE and Vanover KE (1993) 5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions. Psychopharmacology, 112, 1-12.
18. Beck AT (1976) Cognitive Therapy of the Emotional Disorders. New American Library, New York.
19. Beck AT and Emery G (1985) Anxiety Disorders and Phobias. A Cognitive Perspective. Basic Books, New York.
20. Belzung C and LePape G (1994) Comparison of different behavioural test situations used in psychopharmacology for the measurement of anxiety. Physiology and Behavior, 56, 623-628.
21. Belzung C, Pineau N, Beuzen A and Misslin R (1994) PD135158, a CCK-B antagonist, reduces 'state' but not 'trait' anxiety in mice. Pharmacology, Biochemistry and Behavior, 49, 433-436.
22. Berton O, Ramos A, Chaouloff F and Mormede P (1997) Behavioural reactivity to social and nonsocial stimulations: a multivariate analysis of six inbred rat strains. Behavior Genetics, 27, 155-166.
23. Blanchard RJ and Blanchard DC (1969) Passive and active reactions to fear-eliciting stimuli. Journal of Comparative and Physiological Psychology, 68, 129-135.
24. Blanchard RJ and Blanchard DC (1989) Anti-predator defensive behaviors in a visible burrow system. Journal of Comparative Psychology, 103, 70-82.
25. Blanchard RJ, Fukunaga K, Blanchard DC and Kelley MJ (1975) Conspecific aggression in the laboratory rat. Journal of Comparative and Physiological Psychology, 89, 1204-1209.
26. Blanchard RJ, Blanchard DC, Takahashi T and Kelley MJ (1977) Attack and defensive behavior in the albino rat. Animal Behaviour, 25, 622-634.
27. Blanchard RJ, Flannelly KJ and Blanchard DC (1986) Defensive behaviors of laboratory and wild Rattus norvegicus. Journal of Comparative Psychology, 100, 101-107.
28. 1A agonists, buspirone and gepirone. Pharmacology, Biochemistry and Behavior, 31, 269-278.
29. Blanchard DC, Rodgers RJ, Hori K, Hendrie CA and Blanchard RJ (1989) Attenuation of defensive threat and attack in wild rats (Rattus rattus) by benzodiazepines. Psychopharmacology, 91, 392-401.
30. Blanchard DC, Blanchard RJ and Rodgers RJ (1990a) Pharmacological and neural control of anti-predator defense in the rat. Aggressive Behavior, 16, 165-175.
31. Blanchard DC, Blanchard RJ, Tom P and Rodgers RJ (1990b) Diazepam alters risk assessment in an anxiety/defense test battery. Psychopharmacology, 101, 511-518.
32. Blanchard DC, Blanchard RJ and Rodgers RJ (1991a) Risk assessment and animal models of anxiety. In: Animal Models in Psychopharmacology (Eds B Olivier, J Mos and JL Slangen), pp. 117-134. Birkhauser, Basel.
33. Blanchard RJ, Blanchard DC, Agullana R and Weiss SM (1991b) Twenty-two kHz cries to presentation of a predator, by laboratory rats living in visible burrow systems. Physiology and Behavior, 50, 967-972.
34. Blanchard DC, Shepherd JK, Rodgers RJ and Blanchard RJ (1992) Evidence for differential effects of 8-OH-DPAT on male and female rats in the Anxiety/Defense Test Battery. Psychopharmacology, 106, 531-539.
35. Blanchard RJ, Yudko EB, Rodgers RJ and Blanchard DC (1993) Defense system psychopharmacology: an ethological approach to the pharmacology of fear and anxiety. Behavioral Brain Research, 58, 155-165.
36. Blanchard RJ, Parmigiani S, Agullana R, Weiss SM and Blanchard DC (1995a) Behaviors of Swiss-Webster and C57/ BL/6N sin mice in a fear/defense test battery. Aggressive Behavior, 21, 21-28.
37. Blanchard RJ, Parmigiani A, Bjornson C, Masuda C, Weiss SM and Blanchard DC (1995b) Antipredator behavior of Swiss-Webster mice in a visible burrow system. Aggressive Behavior, 21, 123-136.
38. Bolles RC (1970) Species-specific defense reactions and avoidance learning. Psychological Review, 77, 32-48.
39. Bremner JD and Charney DS (1994) Neurobiology of posttraumatic stress disorder. Implications for treatment. In: Current Therapeutic Approaches to Panic and Other Anxiety Disorders (Eds G Darcourt, J Mendlewicz, G Racagni and N Brunello), pp. 170-186. Karger, Basel.
40. Broekkamp CL, Berendsen HHG, Jenck F and Van Delft AML (1989) Animal models for anxiety and response to serotonergic drugs. Psychopathology, 22 (Suppl 1), 2-12.
41. Brudzynski SM and Ociepa D (1992) Ultrasonic vocalization of laboratory rats in response to handling and touch. Physiology and Behavior, 52, 655-660.
42. 1A receptor antagonist, in the murine elevated plus-maze. Psychopharmacology, 129, 365-371.
43. 1A. Pharmacology, Biochemistry and Behavior, in press.
44. 1A receptor antagonism on plus-maze behaviour in mice. II. WAY 100635, SDZ 216-525 and NAN-190. Pharmacology, Biochemistry and Behavior, in press.
45. Carrive P (1991) Functional organization of PAG neurons controlling regional vascular beds. In: The Midbrain Periaqueductal Gray Matter: Functional, Anatomical and Neurochemical Organization (Eds A Depaulis and RJ Bandler), pp. 67-100. Plenum, New York.
46. Clark DM (1989) Anxiety states: panic and generalized anxiety. In: Cognitive Behaviour Therapy for Psychiatric Problems, a Practical Guide (Eds K Hawton, PM Salkovkis, J Kirk and DM Clark), pp. 52-96. Oxford Medical, Oxford.
47. Cole JC and Rodgers RJ (1993) An ethopharmacological analysis of the effects of chlordiazepoxide and bretazenil (Ro16-6028) in the murine elevated plus-maze. Behavioural Pharmacology, 4, 573-580.
48. Cole JC and Rodgers RJ (1994) Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol. Psychopharmacoloyy, 114, 288-296.
49. Cole JC and Rodgers RJ (1995) Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behaviour of mice in the elevated plus-maze. Pharmacology, Biochemistry and Behavior, 52, 473-478.
50. Costall B, Hendrie CA, Kelly ME and Naylor RJ (1987) Actions of sulpiride and tiapride in a simple model of anxiety in mice. Neuropharmacology, 26, 195-200.
51. Costall B, Kelly ME, Naylor RJ and Tomkins DM (1988) Actions of buspirone in a putative model of anxiety in the mouse. Journal of Pharmacy and Pharmacology, 40, 494-500.
52. Crawley JN and Goodwin FK (1980) Preliminary report of a simple animal behaviour model for the anxiolytic effects of benzodiazepines. Pharmacology, Biochemistry and Behavior, 13, 167-170.
53. Cruz APM, Frei F and Graeff FG (1994) Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacology, Biochemistry and Behavior, 49, 171-176.
54. Cuomo V, Cagiano R, De Salvia MA, Masell MA, Renna G and Racagni G (1988) Ultrasonic vocalization in response to unavoidable aversive stimuli in rats: effects of benzodiazepines. Life Sciences, 43, 485-491.
55. Dalvi A and Rodgers RJ (1996) GABAergic influences on plus-maze behavior in mice. Psychopharmacology, 128, 380-397.
56. Darwin CR (1872) The Expression of the Emotions in Man and Animals. John Murray, London.
57. Davis M, Falls WA, Campeau S and Kim M (1993) Fear-potentiated startle: a neural and pharmacological analysis. Behavioral Brain Research, 58, 175-198.
58. Dawson GR and Tricklebank MD (1995) Use of the elevated plus-maze in the search for novel anxiolytic agents. Trends in Pharmacological Sciences, 16, 33-36.
59. Deakin JFW and Graeff FG (1991) 5-HT and mechanisms of defence. Journal of Psychopharmacology, 5, 305-315.
60. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology, 121, 1-26.
61. DeVry J, Benz U, Schreiber R and Traber J (1993) Shock-induced ultrasonic vocalization in young adult rats: a novel model for testing putative anti-anxiety drugs. European Journal of Pharmacology, 249, 331-339.
62. Edmunds M (1974) Defence in Animals: A Survey of Anti-Predator Defences. Longmans, London.
63. Endler JA (1986) Defence against predators. In: Predator-Prey Relationships (Eds ME Feder and GV Lauder), pp. 109-134. University of Chicago Press, Chicago.
64. Falter U, Gower AJ and Gobert J (1992) Resistance of baseline activity in the elevated plus-maze to exogenous influences. Behavioural Pharmacology, 3, 123-128.
65. Fanselow MS (1982) The post-shock activity burst. Animal Learning and Behavior, 10, 448-454.
66. Fernandes C and File SE (1996) The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacology, Biochemistry and Behavior, 54, 31-40.
67. File SE (1990) One-trial tolerance to the anxiolytic effects of benzodiazepines in the plus-maze. Psychopharmacology, 100, 281-282.
68. File SE (1992) Behavioural detection of anxiolytic action. In: Experimental Approaches to Anxiety and Depression (Eds JM Elliott, DJ Heal and CA Marsden), pp. 25-44. J Wiley, Chichester.
69. File SE and Hyde JR (1978) Can social interaction be used to measure anxiety? British Journal of Pharmacology, 62, 19-24.
70. File SE and Zangrossi H (1993) 'One trial tolerance' to the anxiolytic actions of benzodiazepines in the elevated plus-maze, or the development of a phobic state? Psychopharmacology, 110, 240-244.
71. File SE, Zangrossi H and Andrews N (1993a) Social interaction and elevated plus-maze tests: changes in release and uptake of 5-HT and GABA. Neuropharmacology, 32, 217-221.
72. File SE, Zangrossi H, Viana M and Graeff FG (1993b) Trial 2 in the elevated plus-maze: a different form of fear? Psychopharmacology, 111, 491-494.
73. 1A receptor modulation of anxiety in two ethological animal tests. Journal of Neuroscience, 16, 4810-4815.
74. Fontana DJ, Carbary TJ and Commissaris RL (1989) Effects of acute and chronic anti-panic drug administration on conflict behavior in the rat. Psychopharmacology, 98, 157-162.
75. Gardner CR (1985) Distress vocalization in rat pups: a simple screening method for anxiolytic drugs. Journal of Pharmacological Methods, 14, 181-187.
76. Goa KL and Ward A (1986) Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs, 32, 114-129.
77. Graeff FG (1991) Neurotransmitters in the dorsal periaqueductal grey and animal models of panic anxiety. In: New Concepts in Anxiety (Eds M Briley and SE File), pp. 288-312. MacMillan, London.
78. Grant EC and Mackintosh JH (1963) A comparison of the social postures of some common laboratory rodents. Behaviour, 21, 246-259.
79. Green S and Hodges H (1991) Animal models of anxiety. In: Behavioural Models in Psychopharmacology (Ed P Willner), pp. 21-29. CUP, Cambridge.
80. Griebel G (1995) 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacology and Therapeutics, 65, 319-395.
81. Griebel G, Moreau J-L, Jenck F, Martin JR and Misslin R (1993) Some critical determinants of the behaviour of rats in the elevated plus-maze. Behavioural Processes, 29, 37-48.
82. Griebel G, Blanchard DC, Agnes RS and Blanchard RJ (1995a) Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic treatment with imipramine and fluoxetine. Psychopharmacology, 120, 57-66.
83. Griebel G, Blanchard DC, Jung A and Blanchard RJ (1995b) A model of 'antipredator' defense in Swiss-Webster mice: effects of benzodiazepine receptor ligands with different intrinsic activities. Behavioural Pharmacology, 6, 732-745.
84. Griebel G, Blanchard DC, Jung A, Lee JC, Masuda CK and Blanchard RJ (1995c) Further evidence that the Mouse Defense Test Battery is useful in screening anxiolytic and panicolytic drugs: effects of acute and chronic treatment with alprazolam. Neuropharmacology, 34, 1625-1633.
85. 2A antagonist pirenpirone. Pharmacology, Biochemistry and Behavior, 51, 235-244.
86. Griebel G, Blanchard DC and Blanchard RJ (1996a) Evidence that the behaviors in the Mouse Defense Test Battery relate to different emotional states: a factor analytic study. Physiology and Behavior, 60, 1255-1260.
87. Griebel G, Blanchard DC and Blanchard RJ (1996b) Predator-elicited flight responses in Swiss-Webster mice: an experimental model of panic attacks. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 20, 185-205.
88. Griebel G, Sanger DJ and Perrault G (1996c) The Mouse Defense Test Battery: evaluation of the effects of non-selective and BZ-1 (ω1) selective, benzodiazepine receptor ligands. Behavioural Pharmacology, 6, 560-572.
89. Griebel G, Rodgers RJ, Perrault G and Sanger DJ (1997a) Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze. Pharmacology, Biochemistry and Behavior, 57, 817-827.
90. Griebel G, Sanger DJ and Perrault G (1997b) Genetic differences in the mouse defense test battery. Aggressive Behavior, 23, 19-31.
91. Hall CS (1934) Emotional behavior in the rat. I. Defecation and urination as measures of individual differences in emotionality. Journal of Comparative Psychology, 18, 385-403.
92. Handley SL (1991) Serotonin in animal models of anxiety: the importance of stimulus and response. In: Serotonin, Sleep and Mental Disorder (Eds C Idzikowski and PJ Cowen), pp. 89-115. Wrightson, London.
93. Handley SL and Mithani S (1984) Effects of alpha-adrenoceptor agonists and antagonists in a maze exploration model of 'fear'-motivated behaviour. Naunyn-Scmiedeberg's Archives of Pharmacology, 327, 1-5.
94. Handley SL, McBlane JW, Critchley MAE and Njung'e K (1993) Multiple serotonin mechanisms in animal models of anxiety: environmental, emotional and cognitive factors. Behavioral Brain Research, 58, 203-210.
95. Hendrie CA and Neill JC (1991) An animal model of panic disorder. Journal of Psychopharmacology, 6, 125.
96. Hogg S (1996) A review of the validity and reliability of the elevated plus-maze as a model of anxiety. Pharmacology, Biochemistry and Behavior, 54, 21-30.
97. Holmes A and Rodgers RJ (1996) Factor analysis of behavioural responses to repeated testing in the plus-maze. Journal of Psychopharmacology, 10 (Suppl), A47, 185.
98. 3 receptors. Psychopharmacology, 97, 489-495.
99. 1C) receptors on periaqueductal gray aversion. European Journal of Pharmacology, 161, 219-221.
100. Jenck F, Broekkamp CLE and van Delft AML (1990) The effect of antidepressants on aversive periaqueductal gray stimulation in rats. European Journal of Pharmacology, 177, 201-204.
101. Jenck F, Moreau J-L and Martin JR (1995) Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Psychiatry Research, 57, 181-191.
102. B receptor ligands in a validated simulation of panic anxiety in rats. European Neuro-Psychopharmacology, 6, 291-298.
103. B) receptor ligands in the elevated plus-maze test of anxiety in mice. Psychopharmacology, 124, 355-364.
104. Kaesermann H-P (1986) Stretched attend posture, a non-social form of ambivalence is sensitive to a conflict-reducing drug action. Psychopharmacology, 89, 31-37.
105. Kidman A (1989) Neurochemical and cognitive aspects of anxiety disorders. Progress in Neurobioloyy, 32, 391-402.
106. Kostowski W, Plaznik A and Stefanski R (1989) Intra-hippocampal buspirone in animal models of anxiety. European Journal of Pharmacology, 168, 393-396.
107. Kramer MS, Cutler NR, Ballenger JC, Patterson WM, Mendels J, Cheault A, Shrivastava R, Matzurawolfe D, Lines C and Reines S (1995) A placebo-controlled trial of L-365-260, a CCK-B antagonist, in panic disorder. Biological Psychiatry, 37, 462-466.
108. 3 Antagonists and Benzodiazepines: Their Comparative Behavioural Pharmacology (Eds RJ Rodgers and SJ Cooper), pp. 343-363. J Wiley, Chichester.
109. Lal H and Emmett-Oglesby MW (1983) Behavioral analogues of anxiety. Animal models. Neuropharmacology, 22, 1423-1441.
110. Lecrubier Y, Puech AJ, Azcona A, Bailey PE and Lataste (1993) A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology, 112, 129-133.
111. LeDoux JE (1995) Emotion: clues from the brain. Annual Review of Psychology, 46, 209-235.
112. Lee C and Rodgers RJ (1990) Antinociceptive effects of plus-maze exposure: influence of opiate receptor manipulations. Psychopharmacology, 102, 507-513.
113. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology, 92, 180-185.
114. Lister RG (1990) Ethologically based animal models of anxiety disorders. Pharmacology and Therapeutics, 46, 321-340.
115. Lovick TA (1993) Integrated activity of cardiovascular and pain regulatory systems: role in adaptational behavioural responses. Progress in Neurobiology, 40, 631-644.
116. Marks IM (1987) Fears, Phobias and Rituals. OUP, New York.
117. Marks IM and Nesse RM (1994) Fear and fitness: an evolutionary analysis of anxiety disorders. Ethology and Sociobiology, 15, 247-261.
118. Martin JR (1993) Effects of anxiolytic and antidepressant drugs in an animal model of panic. In: Anxiety: Neurobiology, Clinical and Therapeutic Perspectives (Eds M Hamon, H Ollat and MH Thiebot), pp. 203-204. Libbey, Paris.
119. McCreary AC, McBlane JW, Spooner HA and Handley SL (1996) 5-HT system and anxiety: multiple mechanisms in the elevated plus-maze. Polish Journal of Pharmacology, 48, 1-12.
120. McNaughton N (1997) Cognitive dysfunction resulting from hippocampal hyperactivity - a possible cause of anxiety disorder? Pharmacology, Biochemistry and Behavior, 56, 603-611.
121. A and 5-HT anxiolytics. Psychopharmacology, 121, 38-56.
122. Molewijk HE, van der Poel AM and Olivier B (1995a) The ambivalent 'stretched attend posture' in the rat as a paradigm to characterize anxiolytic drugs. Psychopharmacology, 121, 81-90.
123. Molewijk HE, van der Poel AM, Mos J, van der Heyden JAM and Olivier B (1995b) Conditioned ultrasonic distress vocalisations in adult male rats as a behavioural paradigm for screening anti-panic drugs. Psychopharmacology, 117, 32-40.
124. Moser PC (1989) An evaluation of the plus-maze test using the novel anxiolytic buspirone. Psychopharmacology, 99, 48-53.
125. Nashold BS, Wilson WP and Slaughter DG (1969) Sensations evoked by stimulation of the midbrain in man. Journal of Neurosurgery, 30, 14-24.
126. Norman TR and Judd FK (1989) Panic attacks, buspirone and serotonin function. Lancet, II, 15.
127. Nutt DJ (1990) The pharmacology of human anxiety. Pharmacology and Therapeutics, 47, 233-266.
128. Olds ME and Olds J (1963) Approach-avoidance analysis of the rat diencephalon. Journal of Comparative Neurology, 120, 259-295.
129. Pavlov IP (1941) An example of an experimentally produced neurosis and its treatment in the weak type of nervous system. In: Conditioned Reflexes and Psychiatry (ed IP Pavlov) Vol 2, pp. 95-97, translated by WH Gannt, International Publishers, New York.
130. Pellis S M (1997) Targets and tactics: the analysis of moment-to-moment decision making in animal combat. Aggressive Behavior, 23, 107-129.
131. Pellow S, Chopin P, File SE and Briley M (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. Journal of Neuroscience Methods, 14, 149-167.
132. Pinel JP and Treit D (1978) Burying as a defensive response in rats. Journal of Comparative and Physiological Psychology, 92, 708-712.
133. Pinel J P and Mana MJ (1989) Adaptive interactions of rats with dangerous inanimate objects: support for a cognitive theory of defensive behavior. In: Ethoexperimental Approaches to the Study of Behavior (Eds RJ Blanchard, PF Brain, S Parmigiani and DC Blanchard), pp. 137-155. Kluwer, Dordrecht.
134. Ramos A, Berton O, Mormede P and Chaouloff F (1997) A multiple-test study of anxiety-related behaviours in six inbred rat strains. Behavioral Brain Research, 85, 57-69.
135. Randall LO (1960) Pharmacology of methaminodiazepoxide. Disorders of the Nervous System, 21, 7-10.
136. Rickels K, Downing R, Schweizer E and Hassman H (1993) Antidepressants for the treatment of generalized anxiety disorder. Archives of General Psychiatry, 50, 884-895.
137. Rodgers RJ (1981) Pain and aggression. In: The Biology of Aggression (Eds PF Brain and D Benton), pp. 519-527. Sijthoff/Noordhoff, Amsterdam.
138. 3 Antagonists and Benzodiazepines: Their Comparative Behavioural Pharmacology (Eds RJ Rodgers and SJ Cooper), pp. 195-231. J Wiley, Chichester.
139. Rodgers RJ (1991b) A step in the right direction. Journal of Psychopharmacology, 5, 316-319.
140. Rodgers RJ and Cole JC (1994) The elevated plus-maze: pharmacology, methodology and ethology. In: Ethology and Psychopharmacology (Eds SJ Cooper and CA Hendrie), pp. 9-44. J Wiley, Chichester.
141. Rodgers RJ and Johnson NJT (1995a) Cholecystokinin and anxiety: promises and pitfalls. Critical Reviews in Neurobiology, 9, 345-369.
142. Rodgers RJ and Johnson NJT (1995b) Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacology, Biochemistry and Behavior, 52, 297-303.
143. Rodgers RJ and Shepherd JK (1993) Influence of prior maze experience on behaviour and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice. Psychopharmacology, 113, 237-242.
144. Rodgers RJ and Waters AJ (1985) Benzodiazepines and their antagonists: a pharmacoethological analysis with particular reference to their actions on 'aggression'. Neuroscience and Biobehavioral Reviews, 9, 21-36.
145. Rodgers RJ, Cole JC, Cobain MR, Daly P, Doran PJ, Eells JR and Wallis P (1992a) Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus-maze: profile comparisons with 8-OH-DPAT, CGS12066B, TFMPP and mCPP. Behavioural Pharmacology, 3, 621-634.
146. Rodgers RJ, Cole JC, Dobson MJ and Eells JR (1992b) Effects of fluprazine and eltoprazine in the mouse elevated plus-maze and light/dark exploration tests of anxiety. Journal of Psychopharmacology, 6 (Suppl Abstract Book), A52.
147. Rodgers RJ, Lee C and Shepherd JK (1992c) Effects of diazepam on behavioural and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience. Psychopharmacology, 106, 102-110.
148. 1A receptor agonist, flesinoxan. European Journal of Pharmacology, 261, 321-325.
149. Rodgers RJ, Johnson NJT, Cole JC, Dewar CV, Kidd GR and Kimpson PH (1996) Plus-maze retest profile: importance of initial stages of trial 1 and response to post-trial cholinergic receptor blockade in mice. Pharmacology, Biochemistry and Behavior, 54, 41-50.
150. Rodgers, RJ, Cao B-J, Dalvi A and Holmes A (1997a) Animal models of anxiety: an ethological perspective. Brazilian Journal of Medical and Biological Research, 30, 289-304.
151. Rodgers RJ, Cutler MG and Jackson JE (1997b) Behavioural effects in mice of subchronic chlordiazepoxide, maprotiline and fluvoxamine. II. The elevated plus-maze. Pharmacology, Biochemistry and Behavior, 57, 127-136.
152. Sanger DJ (1991) Animal models of anxiety and the screening and development of novel anxiolytic drugs. In: Neuromethods: Vol. 19: Animal Models in Psychiatry (Eds A BoutIon, G Baker and M Martin-Iverson), pp. 147-198. Humana Press, New York.
153. Sano K, Sekino H and Mayanagi Y (1972) Results of stimulation and destruction of posterior hippocampus in cases with violent, aggressive and restless behaviours. In: Psychosurgery (Ed E Hitchcock, L Laitinen and K Vaernet), pp. 57-71. Thomas, Springfield.
154. Schmitt P, Sandner G and Karki P (1981) Escape and approach induced by brain stimulation: a parametric analysis. Behavioral Brain Research, 2, 49-79.
155. 3 Antagonists and Benzodiazepines: Their Comparative Behavioural Pharmacology (Eds RJ Rodgers and SJ Cooper), pp. 365-376. J. Wiley, Chichester.
156. Scott JP (1981) The evolution and function of agonistic behavior. In: Multidisciplinary Approaches to Aggression Research (Eds PF Brain and D Benton), pp. 129-157. Elsevier, Amsterdam.
157. Siegel A and Pott CB (1988) Neural substrates of aggression and flight in the cat. Progress in Neurobiology, 31, 261-283.
158. Sheehan DV, Raj AB, Sheehan KH and Soto S (1990) Is buspirone effective for panic disorder? Journal of Clinical Psychopharmacology, 10, 3-11.
159. Shepherd JK (1992) Preliminary analysis of an elevated 'zero-maze' as a model of anxiety in laboratory rats. Journal of Psychopharmacology, 6, A56, 223.
160. Shepherd JK, Grewal SS, Fletcher A, Bill DJ and Dourish CT (1994) Behavioural and pharmacological characterization of the elevated zero-maze as an animal model of anxiety. Psychopharmacology, 116, 56-64.
161. 1A receptor agonists and L-5-HTP in Montgomery's conflict test. Pharmacology, Biochemistry and Behavior, 32, 259-265.
162. Stephens DN and Andrews JS (1991) Screening for anxiolytic drugs. In: Behavioural Models in Psychopharmacology (Ed P Willner), pp. 50-75. CUP, Cambridge.
163. Stephens DN, Meldrum BS, Weidmann R, Schneider C and Grutzner M (1986) Does the excitatory amino acid receptor antagonist 2-APH exhibit anxiolytic activity? Psychopharmacology, 90, 166-169.
164. Tancer ME and Uhde TW (1995) Social phobia: a review of pharmacological treatments. CNS Drugs, 3, 267-278.
165. Taylor DP and Moon SL (1991) Buspirone and related compounds as alternative anxiolytics. Neuropeptides, 19 (Suppl), 15-19.
166. Tompkins EC, Clemento AJ, Taylor DP and Perhach JL (1980) Inhibition of aggressive behavior in rhesus monkeys by buspirone. Research Communications in Psychology, Psychiatry and Behavior, 5, 337-352.
167. Treit D (1985) Animal models for the study of anti-anxiety agents: a review. Neuroscience and Biobehavioral Reviews, 9, 209-222.
168. 3 Antagonists and Benzodiazepines: Their Comparative Behavioural Pharmacology (Eds RJ Rodgers and SJ Cooper), pp. 107-131. J Wiley, Chichester.
169. Treit D (1994) Animal models of anxiety and anxiolytic drug action. In: Handbook of Depression and Anxiety (Eds JA den Boer and JMA Sitsen), pp. 201-224. Marcel Dekker, New York.
170. Treit D and Fundytus M (1989) Thigmotaxis as a test of anxiolytic activity in rats. Pharmacology, Biochemistry and Behavior, 31, 959-962.
171. Treit D, Menard J and Royan C (1993a) Anxiogenic stimuli in the elevated plus-maze. Pharmacology, Biochemistry and Behavior, 44, 463-469.
172. Treit D, Pesold C and Rotzinger S (1993b) Dissociating the anti-fear effects of septal and amygdaloid lesions uisng two pharmacologically validated models of rat anxiety. Behavioral Neuroscience, 107, 770-785.
173. Trullas R and Skolnick P (1993) Differences in fear motivated behaviors among inbred mouse strains. Psychopharmacology, 111, 323-331.
174. Tyrer P and Tyrer J (1994) Antidepressive drugs for treatment of anxiety disorders - and vice versa. In: Handbook of Depression and Anxiety (Eds JA den Boer and JMA Sitsen), pp. 497-514. Marcel Dekker, New York.
175. Van der Poel AM, Noach EJK and Miczek KA (1989) Temporal patterning of ultrasonic distress calls in the adult rat: effects of morphine and benzodiazepines. Psychopharmacology, 97, 147-148.
176. Walsh RN and Cummins RA (1976) The open-field test: a critical review. Psychological Bulletin, 83, 482-504.
177. Westenberg HGM and den Boer JA (1993) Serotonin in anxiety-related disorders. In: Serotonin, From Cell Biology to Pharmacology and Therapeutics (Eds PM Vanhoutte, PR Saxena, R Paoletti, N Brunello and AS Jackson), pp. 249-254. Kluwer, Dordrecht.
178. Westenberg HGM and den Boer JA (1994) The neuropharmacology of anxiety: a review on the role of serotonin. In: Handbook of Depression and Anxiety (Eds JA den Boer and JMA Sitsen), pp. 405-446. Marcel Dekker, New York.
179. 1A agonist, in the treatment of panic disorder. Clinical Neuropharmacology, 15 (suppl), 60.
180. Wright IK, Upton N and Marsden CA (1992) Effect of established and putative anxiolytics on extracellular 5-HT and 5-HIAA in the ventral hippocampus of rats during behaviour on the elevated X-maze. Psychopharmacology, 109, 338-346.